Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study
European Journal of Nuclear Medicine and Molecular Imaging · 2026-02 · 53 (3) · 1570-1580
DOI: 10.1007/s00259-025-07504-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 06.09.2025. Verfasst von Christos Sachpekidis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. c.sachpekidis@…. Hauptthemen laut MEDLINE: Melanoma, Positron Emission Tomography Computed Tomography, Uveal Neoplasms, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Krebsforschungszentrum (DKFZ).
Abstract (Originalsprache)
Purpose
Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [ 18 F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy. Materials and methods Fifteen patients with mUM treated with tebentafusp underwent [ 18 F]FDG LAFOV PET/CT at baseline and 3 months post-treatment. Total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) were quantified using a deep learning-based segmentation tool On the RECOMIA platform. Metabolic response was assessed according to AI-assisted PERCIST 1.0 criteria. Associations between PET-derived parameters and overall survival (OS) were evaluated using Kaplan–Meier survival analysis.
Results
The median follow up (95% CI) was 14.1 months (12.9 months – not available). Automated TMTV and TLG measurements were successfully obtained in all patients. Elevated baseline TMTV and TLG were significantly associated with shorter OS (TMTV: 16.9 vs. 27.2 months; TLG: 16.9 vs. 27.2 months; p < 0.05). Similarly, higher TMTV and TLG at 3 months post-treatment predicted poorer survival outcomes (TMTV: 14.3 vs. 24.5 months; TLG: 14.3 vs. 24.5 months; p < 0.05). AI-assisted PERCIST response evaluation identified six patients with disease control (complete metabolic response, partial metabolic response, stable metabolic disease) and nine with progressive metabolic disease. A trend toward improved OS was observed in patients with disease control (24.5 vs. 14.6 months, p = 0.08). Circulating tumor DNA (ctDNA) levels based on GNAQ and GNA11 mutations were available in 8 patients; after 3 months Of tebentafusp treatment, 5 showed reduced Or stable ctDNA levels, and 3 showed an increase (median OS: 24.5 vs. 3.3 months; p = 0.13). Patients with increasing ctDNA levels exhibited significantly higher TMTV and TLG on follow-up imaging.
Conclusion
AI-assisted whole-body quantification of [1⁸F]FDG PET/CT and PERCIST-based response assessment are feasible and hold prognostic significance in tebentafusp-treated mUM. TMTV and TLG may serve as non-invasive imaging biomarkers for risk stratification and treatment monitoring in this malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. c.sachpekidis@dkfz-heidelberg.de.
- Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
- Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID-Profile: Christos Sachpekidis
Förderung
- Deutsches Krebsforschungszentrum (DKFZ)
Zitieren
APA
Sachpekidis, C., Machiraju, D., Strauss, D. S., Pan, L., Kopp-Schneider, A., Edenbrandt, L., Dimitrakopoulou-Strauss, A., & Hassel, J. C. (2026). Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 1570-1580. https://doi.org/10.1007/s00259-025-07504-8
Vancouver
Sachpekidis C, Machiraju D, Strauss DS, Pan L, Kopp-Schneider A, Edenbrandt L, et al. Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(3):1570-1580. doi:10.1007/s00259-025-07504-8
BibTeX
@article{Sachpekidis2026,
author = {Sachpekidis, Christos and Machiraju, Devayani and Strauss, Dimitrios Stefanos and Pan, Leyun and Kopp-Schneider, Annette and Edenbrandt, Lars and Dimitrakopoulou-Strauss, Antonia and Hassel, Jessica C},
title = {Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {3},
pages = {1570--1580},
doi = {10.1007/s00259-025-07504-8}
}
EUVIMED